First-in-Human trial: engineered immune cells battle deadly heart shock
NCT ID NCT07380659
Summary
This early-stage study is testing a new cell therapy for people who have a severe heart attack that leads to cardiogenic shock, a dangerous condition where the heart can't pump enough blood. Researchers are giving patients specially engineered immune cells from healthy donors, designed to target scar tissue and calm the harmful inflammation that worsens the shock. The main goal is to see if this treatment is safe and to gather early signs of whether it helps patients recover.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STEMI - ST ELEVATION MYOCARDIAL INFARCTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Second Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, 310009, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.